Research Papers:

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III

Haiyong Wang, Jingze Zhang, Fang Shi, Chenyue Zhang, Qinghua Jiao and Hui Zhu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:34923-34934. https://doi.org/10.18632/oncotarget.16823

Metrics: PDF 1956 views  |   HTML 2242 views  |   ?  


Haiyong Wang1, Jingze Zhang1, Fang Shi1, Chenyue Zhang2, Qinghua Jiao3, Hui Zhu1

1Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan 250117, China

2Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

3Cancer Center, The Second Hospital of Shandong University, Shandong 250033, China

Correspondence to:

Haiyong Wang, email: [email protected]

Hui Zhu, email: [email protected]

Keywords: small cell lung cancer, young, cancer specific survival, SEER

Received: September 16, 2016     Accepted: March 24, 2017     Published: April 04, 2017


It has been reported that younger patients with non-small cell lung cancer (NSCLC) tend to have a better prognosis. Yet, few studies have focused on the clinicopathological characteristics and prognosis of young small cell lung cancer (SCLC), especially for patients with age < 50. In our study, we used Surveillance, Epidemiology, and End Results (SEER) population-based data and identified 16503 patients with SCLC including 711 patients aged < 50, 3338 patients aged 50–59, 5937 patients aged 60–69, 4649 patients aged 70–79 and 1868 patients aged ≥ 80 between 2010 and 2013. The Kaplan-Meier methods was used to develop the survival curve, and the results showed that the SCLC patients with aged < 50 tended to a better over survival (OS) and cancer specific survival (CSS) (all, P < 0.001). In addition, Cox regression model was used to analyze survival prognosis factors and perform subgroup analysis. The results showed that age was an independent prognostic factor for CSS (P < 0.001). Importantly, we found that for the patients with AJCC stage III subgroup, the age < 50 had apparent CSS benefit compared with any other age group (all, P < 0.01). Interestingly, for the patients with no surgery, radiation and no radiation subgroup, the age < 50 had no apparent CSS benefit only compared with age 50–59 (all, P > 0.05). In conclusion, our study demonstrated that the SCLC patients with aged < 50 tended had a better survival benefit, especially for patients with AJCC stage III.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16823